诺和诺德(NVO.US)昨日大涨超7%后，今日续涨超3%，报53.21美元。消息面上，美国食品药物管理局 (FDA)批准诺和诺德的诺和盈(Wegovy，成分为司美格鲁肽)药片作为口服GLP-1上市。Wegovy口服片是 首个获批用于体重管理的口服GLP-1受体激动剂药物。试验数据显示，服用Wegovy口服片剂所达到的 减肥效果，与注射用Wegovy 2.4毫克类似。(格隆汇) ...

Core Viewpoint - Zhang Yifan will officially join Lingbei China as General Manager on July 1, 2025, succeeding Jens Hoeyer, who has left the position [2][4][3]. Group 1: Leadership Transition - Zhang Yifan will be responsible for all operations of Lingbei in mainland China and Hong Kong, while Yang Shaohua will continue as Vice President focusing on strategic finance, business development, and partnerships [3][6]. - Yang Shaohua has played a crucial role in maintaining strong performance during the transition period [6]. Group 2: Zhang Yifan's Background - Zhang Yifan has 16 years of experience in the global pharmaceutical industry, including significant roles at Novo Nordisk in Denmark, France, Taiwan, and recently in China [5][8]. - He successfully built and led the obesity business unit from scratch in China, launching new products nationwide [5][8]. - Zhang holds a Master's degree in International Business and Trade from the University of Gothenburg, Sweden, and a Bachelor's degree in International Business from Brisbane, Australia [5][8]. Group 3: Future Outlook - The leadership believes that Zhang's extensive cross-functional and regional experience, along with his strategic thinking and management skills, will drive Lingbei China towards its goal of becoming an "innovation-focused" company [5][8].